Questions and answers on DTG use in women of childbearing age

On 18 May 2018, WHO has issued a web statement signalling a potential risk of neural tube defects in infants born to women who were taking dolutegravir (DTG) at the time of conception.

WHO is proactively engaging with countries and partners in addressing policy and programmatic implications of these findings for national HIV programmes. To inform the discussions and to guide decision-making, WHO has also released a "questions and answers" (Q&A) document.

WHO Prequalification is also actively monitoring the situation and the relevant product information for DTG or DTG containing prequalified products will be updated as necessary.